Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Case report

Vaginal metastasis as the initial presentation of leiomyosarcoma: a case report

Authors: Cecilia Villalaín-González, Álvaro Tejerizo-García, Patricia Lopez-Garcia, Gregorio López-González, Ma. Reyes Oliver-Perez, Jesús S. Jiménez-López

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Uterine leiomyosarcomas are very rare and highly aggressive tumors that have a high rate of recurrence and poor prognosis, even when early diagnosed. Due to their relative rarity, there is limited research on optimal management strategies.

Case presentation

A 60-year-old woman with a history of an asymptomatic uterine leiomyoma presented in October 2015 with postmenopausal bleeding and a friable vaginal cyst that bled when palpated. A partial cystectomy was performed, and malignant-like cystic and solid components were identified. Histopathology diagnosed an unclassifiable malignant epithelioid tumor. Subsequent imaging studies identified a malignant uterine tumor, a metabolically active vaginal lesion, and two benign leiomyomas. An anterior pelvic exenteration (colpectomy, hysterectomy, bilateral adnexectomy, total cystectomy, and cutaneous ureteroileostomy ad modum Bricker) were performed by laparotomy in March 2016. Examination of the surgical specimens identified a 75 × 75-mm leiomyoma, an 80 × 30-mm infiltrating mesenchymal uterine lesion with vascular invasion and tumor emboli, and a 60 × 30-mm perivascular vaginal tumor. Immunohistochemistry indicated a phenotypic transition from a uterine leiomyosarcoma to a vaginal epithelioid lesion; marker expression changed from the uterine tumor actin+/desmin+/caldesmon+/CD10− phenotype, through the tumor emboli, to an actin−/desmin−/caldesmon−/CD10+ phenotype in the vaginal lesion. A high-grade uterine mesenchymal tumor and vaginal metastasis were diagnosed. Adjuvant chemotherapy with docetaxel, gemcitabine, and doxorubicin commenced in May 2016 and treatment has been well tolerated.

Conclusions

Differentiating leiomyosarcoma from leiomyoma is challenging and few tools other than microscopic evaluation are available. Vaginal compromise in leiomyosarcoma usually results from tumor extension, not hematogenous metastasis. A vaginal metastasis is a very rare initial presentation. We have found only two cases like this described on published literature. The atypical clinical and histological presentation in our case complicated diagnosis and delayed treatment. An early diagnosis and complete surgical clearance gives the best chance of survival, and imaging tools should be applied early in instances of new suspicious malignant lesions.
Literature
1.
go back to reference Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus: a review. Acta Oncol. 2012;51:694.CrossRefPubMed Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus: a review. Acta Oncol. 2012;51:694.CrossRefPubMed
2.
go back to reference Abeler VM, Royne O, Thorensen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000, including 419 patients. Histopathology. 2009;54:355–64.CrossRefPubMed Abeler VM, Royne O, Thorensen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000, including 419 patients. Histopathology. 2009;54:355–64.CrossRefPubMed
3.
go back to reference D'Angelo E, Prat J. Uterine Sarcomas. GynecolOncol. 2010;116:131–9. D'Angelo E, Prat J. Uterine Sarcomas. GynecolOncol. 2010;116:131–9.
4.
go back to reference FIGO commitee on gynecologic Oncology. FIGO staging for uterine sarcomas. Int J GynObst 2009; 104:179. And corrigendum to “FIGO staging for uterine sarcomas”. Int J GynObst. 2009;106:277. FIGO commitee on gynecologic Oncology. FIGO staging for uterine sarcomas. Int J GynObst 2009; 104:179. And corrigendum to “FIGO staging for uterine sarcomas”. Int J GynObst. 2009;106:277.
5.
go back to reference Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460-9.CrossRefPubMed Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460-9.CrossRefPubMed
6.
go back to reference Amant F, Coosemans A, Renard V, Everaert E, Vergote I.Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int J Gynecol Cancer. 2009;19(2):245–8. Amant F, Coosemans A, Renard V, Everaert E, Vergote I.Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int J Gynecol Cancer. 2009;19(2):245–8.
7.
go back to reference Kobayashi H, Uekuri C, et al. The biology of uterine sarcomas: a review and update. Mol Clin Oncol. 2013;1(4):599–609.PubMedPubMedCentral Kobayashi H, Uekuri C, et al. The biology of uterine sarcomas: a review and update. Mol Clin Oncol. 2013;1(4):599–609.PubMedPubMedCentral
8.
go back to reference Ly A, Mills AM, et al. Atypical Leiomyomas of the uterus. A clinicopathologic study of 51 Cases. Am J Surg Pathol. 2013;37(5):643–9.CrossRefPubMed Ly A, Mills AM, et al. Atypical Leiomyomas of the uterus. A clinicopathologic study of 51 Cases. Am J Surg Pathol. 2013;37(5):643–9.CrossRefPubMed
10.
go back to reference Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol. 2011;30(3):236–43.CrossRefPubMed Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol. 2011;30(3):236–43.CrossRefPubMed
11.
go back to reference Oncoguía SEGO: Sarcomas uterinos. Guías de práctica clínica en cáncer ginecológico y mamario: Publicaciones SEGO; Gynecol Oncol. 2003;89(3):460–9. Oncoguía SEGO: Sarcomas uterinos. Guías de práctica clínica en cáncer ginecológico y mamario: Publicaciones SEGO; Gynecol Oncol. 2003;89(3):460–9.
12.
go back to reference Pautier P, Floquet A, Berton-Rigaud D, Piperno-Neumann S. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: results from 81 randomized patients (abstract 10022). J Clin Oncol. 2011;S:10022.CrossRef Pautier P, Floquet A, Berton-Rigaud D, Piperno-Neumann S. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: results from 81 randomized patients (abstract 10022). J Clin Oncol. 2011;S:10022.CrossRef
13.
go back to reference Cantisani V, Mortele KJ, et al. Vaginal metastasis from uterine leiomyosarcoma. Magnetic resonance imaging features with pathological correlation. J Comput Assist Tomogr. 2003;27(5):805–9.CrossRefPubMed Cantisani V, Mortele KJ, et al. Vaginal metastasis from uterine leiomyosarcoma. Magnetic resonance imaging features with pathological correlation. J Comput Assist Tomogr. 2003;27(5):805–9.CrossRefPubMed
14.
go back to reference del Carmen Binda M, Cejas C, et al. Leiomiosarcoma uterino con metástasis vaginal A propósito de un caso. Revista Argentina de Radiología. 2010;17(1):28–31. vol. 70, núm. 3, julio-septiembre, 2006, pp. 207-212 del Carmen Binda M, Cejas C, et al. Leiomiosarcoma uterino con metástasis vaginal A propósito de un caso. Revista Argentina de Radiología. 2010;17(1):28–31. vol. 70, núm. 3, julio-septiembre, 2006, pp. 207-212
15.
go back to reference Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. ProcNatlAcadSci USA. 2008;105(50):1987.CrossRef Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. ProcNatlAcadSci USA. 2008;105(50):1987.CrossRef
16.
go back to reference Tirumani SH, Ojili V, Shanbhogue AKP, et al. Current concepts in the imaging of uterine sarcoma. Abdom Imaging. 2013;38:397–411.CrossRefPubMed Tirumani SH, Ojili V, Shanbhogue AKP, et al. Current concepts in the imaging of uterine sarcoma. Abdom Imaging. 2013;38:397–411.CrossRefPubMed
17.
go back to reference Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535.CrossRefPubMed Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535.CrossRefPubMed
18.
go back to reference Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. Cancer Genet Cytogenet. 2005;161:1.CrossRefPubMed Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. Cancer Genet Cytogenet. 2005;161:1.CrossRefPubMed
19.
go back to reference Kapp DS, Shin JY. Chan JK prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820.CrossRefPubMed Kapp DS, Shin JY. Chan JK prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820.CrossRefPubMed
20.
go back to reference Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82–8.CrossRefPubMed Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82–8.CrossRefPubMed
22.
go back to reference Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198(218):e1. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198(218):e1.
23.
go back to reference Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98:176.CrossRefPubMed Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98:176.CrossRefPubMed
24.
go back to reference Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12):1188–98.CrossRefPubMed Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12):1188–98.CrossRefPubMed
25.
go back to reference Nam JH, Park JY. Update on treatment of uterine sarcoma. CurrOpinObstet Gynecol. 2010;22:36–42. Nam JH, Park JY. Update on treatment of uterine sarcoma. CurrOpinObstet Gynecol. 2010;22:36–42.
26.
go back to reference Seddon B, Whelan J, Strauss SJ, Leahy MG. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(S1):abstract 10500 Seddon B, Whelan J, Strauss SJ, Leahy MG. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(S1):abstract 10500
27.
go back to reference Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological cancer group study (protocol 55874). Eur J Cancer. 2008;44:808.CrossRefPubMed Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological cancer group study (protocol 55874). Eur J Cancer. 2008;44:808.CrossRefPubMed
28.
go back to reference Galaal K, Godfrey K, Naik R, et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2011;1:CD006812. Galaal K, Godfrey K, Naik R, et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2011;1:CD006812.
29.
go back to reference Garcia C. Kubat JS clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort. Int J Gynecol Cancer. 2015;25(4):622–8. Garcia C. Kubat JS clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort. Int J Gynecol Cancer. 2015;25(4):622–8.
30.
go back to reference Allen MM, Douds JJ. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. Int J Clin Exp Pathol. 2015;8(3):2795–801.PubMedPubMedCentral Allen MM, Douds JJ. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. Int J Clin Exp Pathol. 2015;8(3):2795–801.PubMedPubMedCentral
31.
go back to reference Davidson B, Abeler VM. Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Hum Pathol. 2014;45(4):691–700.CrossRefPubMed Davidson B, Abeler VM. Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Hum Pathol. 2014;45(4):691–700.CrossRefPubMed
32.
go back to reference Hwang H, Matsuo K. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new. J Clin Pathol. 2015;68(9):710–7.CrossRefPubMed Hwang H, Matsuo K. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new. J Clin Pathol. 2015;68(9):710–7.CrossRefPubMed
33.
go back to reference Kurman RJ, Carcangiu ML, Simon Herrington C, Young RH. WHO Classification of tumours of female reproductive organs. Lyon: IARC; 2014. Kurman RJ, Carcangiu ML, Simon Herrington C, Young RH. WHO Classification of tumours of female reproductive organs. Lyon: IARC; 2014.
34.
go back to reference Ravid Y, Formanski M, Smith Y, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. Gynecol Oncol. 2016;140:512–7.CrossRefPubMed Ravid Y, Formanski M, Smith Y, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. Gynecol Oncol. 2016;140:512–7.CrossRefPubMed
Metadata
Title
Vaginal metastasis as the initial presentation of leiomyosarcoma: a case report
Authors
Cecilia Villalaín-González
Álvaro Tejerizo-García
Patricia Lopez-Garcia
Gregorio López-González
Ma. Reyes Oliver-Perez
Jesús S. Jiménez-López
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3484-1

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine